VA
SYRE icon

VR Adviser’s Spyre Therapeutics SYRE Stock Holding History

VR Adviser’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$186M Hold
3,685,448
– – 6.94% 4
2025
Q4 		$121M Buy
3,685,448
+1,000,000
+37% +$26.1M 5.96% 4
2025
Q3 		$45M Hold
2,685,448
– – 2.53% 14
2025
Q2 		$40.2M Hold
2,685,448
– – 3.01% 9
2025
Q1 		$43.3M Hold
2,685,448
– – 3.69% 8
2024
Q4 		$62.5M Hold
2,685,448
– – 4.29% 7
2024
Q3 		$79M Hold
2,685,448
– – 4.14% 6
2024
Q2 		$63.1M Buy
2,685,448
+513,666
+24% +$17.3M 4.02% 9
2024
Q1 		$82.4M Sell
2,171,782
-200,932
-8% -$5.82M 3.92% 4
2023
Q4 		$51.1M Buy
2,372,714
+2,077,680
+704% +$28.6M 3.5% 8
2023
Q3 		$3.61M Buy
295,034
+41,305
+16% +$546K 0.38% 33
2023
Q2 		$2.86M Buy
+253,729
New +$1.2M 0.46% 26

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VR Adviser's SYRE Position: Q1 2026 in Review

VR Adviser held its Spyre Therapeutics (SYRE) position steady in Q1 2026 at 3,685,448 shares worth $186M. The position accounts for 6.94% of the portfolio, ranked #4.

VR Adviser first reported a position in SYRE in Q2 2023 and has held it in 12 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • VR Adviser held 3,685,448 shares of Spyre Therapeutics worth $186M as of Q1 2026.
  • VR Adviser left its Spyre Therapeutics share count unchanged in Q1 2026.
  • Spyre Therapeutics made up 6.94% of VR Adviser's portfolio in Q1 2026, its #4 holding.
  • VR Adviser first reported a position in Spyre Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.